Diese Aktien könnten sich 2016 verdoppeln - 500 Beiträge pro Seite | Diskussion im Forum
eröffnet am 03.07.16 13:52:45 von
neuester Beitrag 22.08.17 10:04:44 von
neuester Beitrag 22.08.17 10:04:44 von
Beiträge: 74
ID: 1.234.582
ID: 1.234.582
Aufrufe heute: 0
Gesamt: 4.592
Gesamt: 4.592
Aktive User: 0
ISIN: US03236M2008 · WKN: A2DS41 · Symbol: AMRSQ
0,0015
USD
+50,00 %
+0,0005 USD
Letzter Kurs 02:10:00 Nasdaq OTC
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 4,7450 | +35,57 | |
| 0,5250 | +19,08 | |
| 5,8900 | +17,80 | |
| 12,800 | +17,43 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,6900 | -14,50 | |
| 2,8150 | -15,21 | |
| 3,0400 | -19,95 | |
| 1,9500 | -25,14 | |
| 0,5121 | -30,80 |
Feedback
Foto: Pixabay, SimonJedes Jahr gibt es einige wenige Aktien, die den Markt überraschen und sich im Vergleich zum Vorjahr verdoppeln. Manchmal wird dieser Anstieg von Makroereignissen ausgelöst, manchmal vom Erfolg des Unternehmens und manchmal …
Lesen Sie den ganzen Artikel: Diese Aktien könnten sich 2016 verdoppeln
Lesen Sie den ganzen Artikel: Diese Aktien könnten sich 2016 verdoppeln
Sollte nächste Woche starten,sehr gute News derzeit und Widerstand bei 0,48 fällt wohl !
American Refining Group Invests in Novvi to Accelerate Amyris Commercialization of Renewable Base Oil and Lubricant Platform
GlobeNewswire•July 19, 2016
CONSHOHOCKEN, Pa. and EMERYVILLE, Calif., July 19, 2016 (GLOBE NEWSWIRE) -- American Refining Group, Inc. (‘ARG’) and Novvi LLC, a joint venture of Amyris, Inc. (AMRS), an integrated renewable products company, and Cosan S.A., one of the largest corporations in Brazil, with businesses in energy, and infrastructure including lubricants, today announced that ARG has committed to a 33.3% equity investment into the joint venture. Both Amyris and Cosan will continue to hold share ownership stakes in Novvi, together with ARG.
Novvi’s products and technology are recognized by the global lubricant market to deliver the best sustainable, high-performance solutions in a range of lubricant applications. ARG’s Bradford, Pennsylvania refinery, founded in 1881, is the oldest continuously operating refinery in North America.
“Our launch of Novvi’s synthetic base oils has been embraced by manufacturers in a range of top-tier lubricant segments, across both automotive and industrial applications,” stated Jeff Brown, Novvi LLC’s CEO. “Our partnership with American Refining Group will help accelerate our growth by providing the necessary resources to ensure manufacturing, supply, and delivery capabilities to scale our business for volume and to meet customer expectations.”
“ARG’s Bradford refinery was built on innovation and market leadership in 1881, and today we are seeing a change in the hydrocarbon economy, coupled with performance requirements in the base oil industry. This is an opportunity for ARG to lead the market once again – this time with a renewable product,” stated Tim Brown, Chief Executive Officer, American Refining Group, Inc. “When we explored the value and synergies, we were struck by the enormous benefit to both companies. The potential benefits cut across our base oil, finished lubricants, solvents, and drilling fluids businesses.”
Tim Brown continued, “Furthermore, environmentally-conscious, energy-efficient products have always been a core interest to ARG and Novvi’s products allow that with Amyris's No Compromise® performance.”
Greater energy efficiency and durability are key growth drivers in high-performance base stocks and lubricants. Together, American Refining Group and Novvi believe that a novel, performance-based, technology platform that couples segment-specific, top-tier performance with sustainable, bio-based feedstocks delivers against the needs of the industry today and in the future.
“We are very pleased with ARG’s financial, technical and commercial support of Novvi and their participation along with the strong demand for Novvi technology enables us to significantly grow into another billion dollar market for our farnesene technology,” said John Melo, President and CEO of Amyris. “This agreement is the first of several we expect this year where we are divesting from non-core marketing activity while remaining key technology developers and producers of high performance chemistry that is remaking the world in a more sustainable way. And, with ARG’s support, we have the opportunity in working together with Cosan to more quickly expand the availability of renewable products into the global markets for base oils and lubricants, which are expected to reach $42 billion and $70 billion in size, respectively, by 2020*. This market is yet another example of how Amyris’s farnesene is able to support the growth of large and diverse markets.”
American Refining Group, Inc.
American Refining Group converts hydrocarbon feedstocks into high-quality waxes, lubricant base oils, gasoline and fuels, as well as a wide variety of specialty products. ARG’s state-of-the-art blending and packaging facilities – located in Bradford, PA -- are capable of producing a full spectrum of finished lubricant products. ARG’s total commitment to quality is proven through our packaging plant and refinery being both ISO 9001:2008 and Made in USA certified; ARG’s was the first refinery to earn the coveted Made in USA certification. See more details on ARG at http://www.amref.com.
Novvi LLC
GlobeNewswire•July 19, 2016
CONSHOHOCKEN, Pa. and EMERYVILLE, Calif., July 19, 2016 (GLOBE NEWSWIRE) -- American Refining Group, Inc. (‘ARG’) and Novvi LLC, a joint venture of Amyris, Inc. (AMRS), an integrated renewable products company, and Cosan S.A., one of the largest corporations in Brazil, with businesses in energy, and infrastructure including lubricants, today announced that ARG has committed to a 33.3% equity investment into the joint venture. Both Amyris and Cosan will continue to hold share ownership stakes in Novvi, together with ARG.
Novvi’s products and technology are recognized by the global lubricant market to deliver the best sustainable, high-performance solutions in a range of lubricant applications. ARG’s Bradford, Pennsylvania refinery, founded in 1881, is the oldest continuously operating refinery in North America.
“Our launch of Novvi’s synthetic base oils has been embraced by manufacturers in a range of top-tier lubricant segments, across both automotive and industrial applications,” stated Jeff Brown, Novvi LLC’s CEO. “Our partnership with American Refining Group will help accelerate our growth by providing the necessary resources to ensure manufacturing, supply, and delivery capabilities to scale our business for volume and to meet customer expectations.”
“ARG’s Bradford refinery was built on innovation and market leadership in 1881, and today we are seeing a change in the hydrocarbon economy, coupled with performance requirements in the base oil industry. This is an opportunity for ARG to lead the market once again – this time with a renewable product,” stated Tim Brown, Chief Executive Officer, American Refining Group, Inc. “When we explored the value and synergies, we were struck by the enormous benefit to both companies. The potential benefits cut across our base oil, finished lubricants, solvents, and drilling fluids businesses.”
Tim Brown continued, “Furthermore, environmentally-conscious, energy-efficient products have always been a core interest to ARG and Novvi’s products allow that with Amyris's No Compromise® performance.”
Greater energy efficiency and durability are key growth drivers in high-performance base stocks and lubricants. Together, American Refining Group and Novvi believe that a novel, performance-based, technology platform that couples segment-specific, top-tier performance with sustainable, bio-based feedstocks delivers against the needs of the industry today and in the future.
“We are very pleased with ARG’s financial, technical and commercial support of Novvi and their participation along with the strong demand for Novvi technology enables us to significantly grow into another billion dollar market for our farnesene technology,” said John Melo, President and CEO of Amyris. “This agreement is the first of several we expect this year where we are divesting from non-core marketing activity while remaining key technology developers and producers of high performance chemistry that is remaking the world in a more sustainable way. And, with ARG’s support, we have the opportunity in working together with Cosan to more quickly expand the availability of renewable products into the global markets for base oils and lubricants, which are expected to reach $42 billion and $70 billion in size, respectively, by 2020*. This market is yet another example of how Amyris’s farnesene is able to support the growth of large and diverse markets.”
American Refining Group, Inc.
American Refining Group converts hydrocarbon feedstocks into high-quality waxes, lubricant base oils, gasoline and fuels, as well as a wide variety of specialty products. ARG’s state-of-the-art blending and packaging facilities – located in Bradford, PA -- are capable of producing a full spectrum of finished lubricant products. ARG’s total commitment to quality is proven through our packaging plant and refinery being both ISO 9001:2008 and Made in USA certified; ARG’s was the first refinery to earn the coveted Made in USA certification. See more details on ARG at http://www.amref.com.
Novvi LLC
Amyris Enters Partnership with Biogen to Develop Alternative Cell Lines Supporting Production of Therapeutics
GlobeNewswire•August 3, 2016
EMERYVILLE, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Amyris, Inc. (AMRS), the industrial bioscience company, is pleased to announce it has entered into a funded partnership with Biogen, Inc. (BIIB). The collaboration will explore the use of Amyris’s advanced microbe engineering technology to evaluate and develop multiple host microorganisms as alternatives to mammalian cell lines for the production of therapeutic recombinant proteins.
“We are pleased to have signed our second major partnership in the biopharma market and we believe with Biogen, the biopharma market is now well positioned to become our largest opportunity for collaborations,” said Cynthia Bryant, Amyris Senior Vice President Corporate Development & Collaborations.
For many recombinant protein therapeutics, mammalian cell lines are engineered to produce the needed protein using a fermentation process. While tremendous progress has been made in increasing productivity, limitations remain.
“Over the course of the partnership, Amyris will utilize its leading strain engineering and screening technology to evaluate the tractability of each selected species as a new potential cell line for recombinant protein production,” explained Joel Cherry, Amyris’s President, Research and Development. “Selected candidates from the initial work will go into a second phase of development to create commercially robust cell lines for use in drug manufacturing.”
About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. The company is delivering its No Compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. More information about the company is available at www.amyris.com.
Forward-Looking Statements
This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as the use of Amyris’s advanced microbe engineering technology to evaluate and develop multiple host microorganisms as alternatives to mammalian cell lines for the production of therapeutic recombinant proteins, the biopharma market becoming Amyris’s largest opportunity for collaborations, and Amyris’s ability to create commercially robust cell lines for use in drug manufacturing), that involve risks and uncertainties. These statements are based on management’s current expectations and actual results and future events may differ materially due to risks and uncertainties, including Amyris's liquidity and ability to fund operating and capital expenses, Amyris's reliance on third parties to achieve its goals, timing and execution risks associated with development and manufacturing, potential delays or failures in development, production and commercialization of products, and other risks detailed in the “Risk Factors” section of Amyris’s quarterly report on Form 10-Q filed on May 10, 2016. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.
Amyris, the Amyris logo are registered trademarks of Amyris, Inc. All other trademarks are the property of their respective owners.
GlobeNewswire•August 3, 2016
EMERYVILLE, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Amyris, Inc. (AMRS), the industrial bioscience company, is pleased to announce it has entered into a funded partnership with Biogen, Inc. (BIIB). The collaboration will explore the use of Amyris’s advanced microbe engineering technology to evaluate and develop multiple host microorganisms as alternatives to mammalian cell lines for the production of therapeutic recombinant proteins.
“We are pleased to have signed our second major partnership in the biopharma market and we believe with Biogen, the biopharma market is now well positioned to become our largest opportunity for collaborations,” said Cynthia Bryant, Amyris Senior Vice President Corporate Development & Collaborations.
For many recombinant protein therapeutics, mammalian cell lines are engineered to produce the needed protein using a fermentation process. While tremendous progress has been made in increasing productivity, limitations remain.
“Over the course of the partnership, Amyris will utilize its leading strain engineering and screening technology to evaluate the tractability of each selected species as a new potential cell line for recombinant protein production,” explained Joel Cherry, Amyris’s President, Research and Development. “Selected candidates from the initial work will go into a second phase of development to create commercially robust cell lines for use in drug manufacturing.”
About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. The company is delivering its No Compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. More information about the company is available at www.amyris.com.
Forward-Looking Statements
This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as the use of Amyris’s advanced microbe engineering technology to evaluate and develop multiple host microorganisms as alternatives to mammalian cell lines for the production of therapeutic recombinant proteins, the biopharma market becoming Amyris’s largest opportunity for collaborations, and Amyris’s ability to create commercially robust cell lines for use in drug manufacturing), that involve risks and uncertainties. These statements are based on management’s current expectations and actual results and future events may differ materially due to risks and uncertainties, including Amyris's liquidity and ability to fund operating and capital expenses, Amyris's reliance on third parties to achieve its goals, timing and execution risks associated with development and manufacturing, potential delays or failures in development, production and commercialization of products, and other risks detailed in the “Risk Factors” section of Amyris’s quarterly report on Form 10-Q filed on May 10, 2016. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.
Amyris, the Amyris logo are registered trademarks of Amyris, Inc. All other trademarks are the property of their respective owners.
Trading Spotlight
Biossance™ Launches The Illuminator ─ A Clinically Proven, Weightless Eye Gel
GlobeNewswire•August 17, 2016
EMERYVILLE, Calif., Aug. 17, 2016 (GLOBE NEWSWIRE) -- Biossance™, the pioneer of sustainable beauty through biotechnology from Amyris, Inc. (AMRS), has introduced The Illuminator, a dual peptide, weightless eye gel with exceptional clinical results.
ILLUMINATOR_LIGHT_FEATHER_HiRes.jpg
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/020528d8-…
“The Illuminator is a fantastic, natural solution designed specifically for the delicate eye area to keep you looking fresh and radiant. It’s essential to have such an innovative product that’s free from harmful ingredients,” said Katey Denno, an A-list celebrity makeup artist known for her extensive knowledge of green beauty.
This new, nontoxic product uses weightless, hydrating, 100% plant-derived squalane with dual peptides to reduce the appearance of dark circles and puffiness along with cell extract from Swiss apples to rejuvenate the delicate skin around the eye area. The product’s ingredients assist with lymphatic drainage supporting a reduction in bagginess around the eyes, which is often associated with lymph fluid pooling under the skin. The Illuminator is also clinically proven to increase cutaneous microcirculation, breaking up the concentration of red blood cells under the eye and reducing the appearance of dark circles.
“The innovative Biossance skincare line, continues to deliver strong sales growth by delivering on consumer demand for natural, high performing products. Just as in food products, today’s educated consumer is increasingly interested in knowing that their skincare products are not detrimental to them, their families, or the planet,” said Caroline Hadfield, Amyris’s Senior Vice President, Personal Care.
The Illuminator is now available at biossance.com along with a full line of products. Each Biossance product is free of harmful ingredients that are commonly used in other brands by using only the good, none of the bad (for more information about Biossance’s high standards please visit the Biossance Blacklist page).
*Ideal for all skin types *Dermatologist tested *Ophthalmologist tested *No parabens
*No synthetic fragrance *Non-toxic *No phthalates *No mineral oil
About Biossance
Biossance™ pioneered sustainable 100% plant-based squalane to replenish your skin and enhance your biological beauty. The squalane-based brand was created in response to the prevalent use of squalane derived from sharks as an emollient in cosmetic products, creating devastating environmental impact. We’ve designed our line of squalane-based products to empower and inform you, so you can trust that what you are putting on your skin is safe. We won’t compromise, so we hand-select the most effective ingredients and avoid those that are potentially harmful to you or the planet. The full Biossance skin care and beauty collection can be found at http://biossance.com.
About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. The company is delivering its No Compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. More information about the company is available at www.amyris.com.
Amyris, the Amyris logo, and Biossance are trademarks or registered trademarks of Amyris, Inc. All other trademarks are the property of their respective owners.
The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.
GlobeNewswire•August 17, 2016
EMERYVILLE, Calif., Aug. 17, 2016 (GLOBE NEWSWIRE) -- Biossance™, the pioneer of sustainable beauty through biotechnology from Amyris, Inc. (AMRS), has introduced The Illuminator, a dual peptide, weightless eye gel with exceptional clinical results.
ILLUMINATOR_LIGHT_FEATHER_HiRes.jpg
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/020528d8-…
“The Illuminator is a fantastic, natural solution designed specifically for the delicate eye area to keep you looking fresh and radiant. It’s essential to have such an innovative product that’s free from harmful ingredients,” said Katey Denno, an A-list celebrity makeup artist known for her extensive knowledge of green beauty.
This new, nontoxic product uses weightless, hydrating, 100% plant-derived squalane with dual peptides to reduce the appearance of dark circles and puffiness along with cell extract from Swiss apples to rejuvenate the delicate skin around the eye area. The product’s ingredients assist with lymphatic drainage supporting a reduction in bagginess around the eyes, which is often associated with lymph fluid pooling under the skin. The Illuminator is also clinically proven to increase cutaneous microcirculation, breaking up the concentration of red blood cells under the eye and reducing the appearance of dark circles.
“The innovative Biossance skincare line, continues to deliver strong sales growth by delivering on consumer demand for natural, high performing products. Just as in food products, today’s educated consumer is increasingly interested in knowing that their skincare products are not detrimental to them, their families, or the planet,” said Caroline Hadfield, Amyris’s Senior Vice President, Personal Care.
The Illuminator is now available at biossance.com along with a full line of products. Each Biossance product is free of harmful ingredients that are commonly used in other brands by using only the good, none of the bad (for more information about Biossance’s high standards please visit the Biossance Blacklist page).
*Ideal for all skin types *Dermatologist tested *Ophthalmologist tested *No parabens
*No synthetic fragrance *Non-toxic *No phthalates *No mineral oil
About Biossance
Biossance™ pioneered sustainable 100% plant-based squalane to replenish your skin and enhance your biological beauty. The squalane-based brand was created in response to the prevalent use of squalane derived from sharks as an emollient in cosmetic products, creating devastating environmental impact. We’ve designed our line of squalane-based products to empower and inform you, so you can trust that what you are putting on your skin is safe. We won’t compromise, so we hand-select the most effective ingredients and avoid those that are potentially harmful to you or the planet. The full Biossance skin care and beauty collection can be found at http://biossance.com.
About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. The company is delivering its No Compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. More information about the company is available at www.amyris.com.
Amyris, the Amyris logo, and Biossance are trademarks or registered trademarks of Amyris, Inc. All other trademarks are the property of their respective owners.
The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.
Biossance™ Launches The Detoxifier ─ A Breakthrough, Innovative Modeling Mask
GlobeNewswire•August 24, 2016
EMERYVILLE, Calif., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Biossance™, the pioneer of sustainable beauty through biotechnology from Amyris, Inc. (AMRS), today launched The Detoxifier, an innovative, new modeling mask for the face. This mask gently detoxifies and deeply hydrates the face, while calming and soothing the skin with squalane.
Detoxifier-Campaign-Visual-600x600.png
Biossance Launches The Detoxifier
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/2cd4fd6c-…
This single-use, peel off modeling mask is the latest in a full line-up of products from Biossance that embodies the brand’s philosophy of providing consumers with safe and sustainable skin care products with well-vetted, high performance ingredients:
100% plant-derived squalane: Instantly hydrates, leaves skin soft and smooth
Alginate (marine algae): Removes toxins from the skin’s surface, restores hydration
Zinc Gluconate: Exfoliates and detoxifies, deep cleans and tightens pores, reduces oiliness, calms skin, and reduces redness
Allantoin: Quenches dry, chapped skin, relieves irritation, gives skin a soft, smooth and healthy appearance.
“I really love the performance of Biossance products on my clients, who trust me to carefully choose cosmetic products that are safe and offer substantial skin benefits. The Detoxifier is a great biodegradable alternative to sheet masks that delivers results,” said Katey Denno, an A-list celebrity makeup artist known for her extensive knowledge of green beauty. “With the full line of products from the Biossance brand, I always know that whatever I reach for to meet my clients’ specific needs will perform and be made from a nontoxic, sustainable source.”
“Our Biossance product portfolio continues to deliver the brand’s No Compromise® commitment of delivering products that are safe, sustainable and best in class performance. Consumers are rewarding us with record sales performance for our brand almost every week this quarter,” said Caroline Hadfield, Amyris’s Senior Vice President, Personal Care.
The Detoxifier is now available at biossance.com along with a full line of products. Each Biossance product is free of harmful ingredients that are commonly used in other brands by using only the good, none of the bad (for more information about Biossance’s high standards please visit the Biossance Blacklist page).
About Biossance
Biossance™ pioneered sustainable 100% plant-based squalane to replenish your skin and restore your biological beauty. The squalane-based brand was created in response to the prevalent use of squalane derived from sharks as an emollient in cosmetic products, creating devastating environmental impact. We’ve designed our line of squalane-based products to empower and inform you, so you can trust that what you are putting on your skin is safe. We won’t compromise, so we hand-select the most effective ingredients and avoid those that are potentially harmful to you or the planet. The full Biossance skin care and beauty collection can be found at http://biossance.com.
About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. The company is delivering its No Compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. More information about the company is available at www.amyris.com.
Amyris, the Amyris logo, Biossance, and No Compromise are trademarks or registered trademarks of Amyris, Inc. All other trademarks are the property of their respective owners.
GlobeNewswire•August 24, 2016
EMERYVILLE, Calif., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Biossance™, the pioneer of sustainable beauty through biotechnology from Amyris, Inc. (AMRS), today launched The Detoxifier, an innovative, new modeling mask for the face. This mask gently detoxifies and deeply hydrates the face, while calming and soothing the skin with squalane.
Detoxifier-Campaign-Visual-600x600.png
Biossance Launches The Detoxifier
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/2cd4fd6c-…
This single-use, peel off modeling mask is the latest in a full line-up of products from Biossance that embodies the brand’s philosophy of providing consumers with safe and sustainable skin care products with well-vetted, high performance ingredients:
100% plant-derived squalane: Instantly hydrates, leaves skin soft and smooth
Alginate (marine algae): Removes toxins from the skin’s surface, restores hydration
Zinc Gluconate: Exfoliates and detoxifies, deep cleans and tightens pores, reduces oiliness, calms skin, and reduces redness
Allantoin: Quenches dry, chapped skin, relieves irritation, gives skin a soft, smooth and healthy appearance.
“I really love the performance of Biossance products on my clients, who trust me to carefully choose cosmetic products that are safe and offer substantial skin benefits. The Detoxifier is a great biodegradable alternative to sheet masks that delivers results,” said Katey Denno, an A-list celebrity makeup artist known for her extensive knowledge of green beauty. “With the full line of products from the Biossance brand, I always know that whatever I reach for to meet my clients’ specific needs will perform and be made from a nontoxic, sustainable source.”
“Our Biossance product portfolio continues to deliver the brand’s No Compromise® commitment of delivering products that are safe, sustainable and best in class performance. Consumers are rewarding us with record sales performance for our brand almost every week this quarter,” said Caroline Hadfield, Amyris’s Senior Vice President, Personal Care.
The Detoxifier is now available at biossance.com along with a full line of products. Each Biossance product is free of harmful ingredients that are commonly used in other brands by using only the good, none of the bad (for more information about Biossance’s high standards please visit the Biossance Blacklist page).
About Biossance
Biossance™ pioneered sustainable 100% plant-based squalane to replenish your skin and restore your biological beauty. The squalane-based brand was created in response to the prevalent use of squalane derived from sharks as an emollient in cosmetic products, creating devastating environmental impact. We’ve designed our line of squalane-based products to empower and inform you, so you can trust that what you are putting on your skin is safe. We won’t compromise, so we hand-select the most effective ingredients and avoid those that are potentially harmful to you or the planet. The full Biossance skin care and beauty collection can be found at http://biossance.com.
About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. The company is delivering its No Compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. More information about the company is available at www.amyris.com.
Amyris, the Amyris logo, Biossance, and No Compromise are trademarks or registered trademarks of Amyris, Inc. All other trademarks are the property of their respective owners.
Damit dürfte die Verdopplung seit dem Erscheinen des Artikel erreicht sein:
Amyris Agrees to Collaboration Terms with Leading Global Food Ingredients and Nutraceuticals Partner
GlobeNewswire•October 13, 2016
EMERYVILLE, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Amyris, Inc. (AMRS), the industrial bioscience company, today announced that it has executed a Memorandum of Understanding for a transformative strategic collaboration with a partner that is a leader in food ingredients and nutraceuticals. Upon required approval and execution of definitive agreements with this new partner, Amyris expects to receive cash representing a short-term collaboration investment of $10 million, an equity investment of up to $20 million at $1.40 per share, $100 million in annual revenue starting in 2017 connected to the production and cost improvement of fermentation molecules, and participation in the partner’s industrial fermentation facilities in Asia.
https://finance.yahoo.com/news/amyris-agrees-collaboration-t…
Gruß Oberländler
Amyris Agrees to Collaboration Terms with Leading Global Food Ingredients and Nutraceuticals Partner
GlobeNewswire•October 13, 2016
EMERYVILLE, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Amyris, Inc. (AMRS), the industrial bioscience company, today announced that it has executed a Memorandum of Understanding for a transformative strategic collaboration with a partner that is a leader in food ingredients and nutraceuticals. Upon required approval and execution of definitive agreements with this new partner, Amyris expects to receive cash representing a short-term collaboration investment of $10 million, an equity investment of up to $20 million at $1.40 per share, $100 million in annual revenue starting in 2017 connected to the production and cost improvement of fermentation molecules, and participation in the partner’s industrial fermentation facilities in Asia.
https://finance.yahoo.com/news/amyris-agrees-collaboration-t…
Gruß Oberländler
Antwort auf Beitrag Nr.: 53.530.971 von gerdass am 22.10.16 13:01:37Hat man sich auf unserer Seite des Teiches ja mal richtig Gedanken gemacht
Der ganze Spaß kostet derzeit schlappe 250 Mio $ in knapp 10 Jahren haben wir hier eine neue Dow Chemical mit >50 Mrd $
KAUFEN und LIEGEN LASSEN - waiting is the hardest part
Bio-based product:
Farnesene
Actors:
Only one market player
,
US-based Amyris.
There are no major European players.
Key markets or applications and value proposition:
Emollients already a key market as
squalane derived from farnesene has
excellent moisturising properties. There is
also potential in the tyre industry due to
superior physical properties compared
with conventional alternatives. For fuels,
the physical and performance properties
are consistent with C15 iso-paraffin.
Cost relative to fossil alternative:
Already an attractive
value proposition in
emollients industry; close
to market in tyre
industry
GHG saved vs. fossil alternative:
Sugarcane-derived
farnesene used as a
diesel or jet fuel can
result in an 80%
reduction in GHG
emissions compared
with conventional
fossil fuels.
European outlook
Amyris has a range of markets into which it
could expand and superior performance in many
cases. As a building block, more applications
could be found in the future. In the EU, the main
opportunities seem to be through partnering
with Amyris on specific applications, which a
number of EU companies appear to be doing.
Seite 76
https://ec.europa.eu/energy/sites/ener/files/documents/EC%20…
Der ganze Spaß kostet derzeit schlappe 250 Mio $ in knapp 10 Jahren haben wir hier eine neue Dow Chemical mit >50 Mrd $
KAUFEN und LIEGEN LASSEN - waiting is the hardest part
Bio-based product:
Farnesene
Actors:
Only one market player
, US-based Amyris.
There are no major European players.
Key markets or applications and value proposition:
Emollients already a key market as
squalane derived from farnesene has
excellent moisturising properties. There is
also potential in the tyre industry due to
superior physical properties compared
with conventional alternatives. For fuels,
the physical and performance properties
are consistent with C15 iso-paraffin.
Cost relative to fossil alternative:
Already an attractive
value proposition
inemollients industry; close
to market in tyre
industry
GHG saved vs. fossil alternative:
Sugarcane-derived
farnesene used as a
diesel or jet fuel can
result in an 80%
reduction in GHG
emissions compared
with conventional
fossil fuels.
European outlook
Amyris has a range of markets into which it
could expand and superior performance in many
cases
. As a building block, more applicationscould be found in the future. In the EU, the main
opportunities seem to be through partnering
with Amyris on specific applications, which a
number of EU companies appear to be doing
.Seite 76
https://ec.europa.eu/energy/sites/ener/files/documents/EC%20…
Antwort auf Beitrag Nr.: 53.531.244 von soulist am 22.10.16 14:00:25http://investorshub.advfn.com/boards/read_msg.aspx?message_i…
Antwort auf Beitrag Nr.: 53.470.506 von Oberlaendler am 13.10.16 15:01:05
Nix für ungut, aber besagter Artikel zur Threaderöffnung erschien am 04.01.2016 und hier in D eine Woche später.
Zitat:
"Amyris Eine weitere Aktie, die sich verdoppeln oder um 50 % fallen könnte ist Amyris (WKN:A1C51H). Das Biotech-Unternehmen hat sehr viel Potenzial und nutzt nach spezielle genetisch veränderte Hefen, um wertvolle Chemikalien für Kunden in verschiedenen Bereichen herzustellen, von Kosmetika bis zu Industrieprodukten und Lebensmitteln. Die Investoren haben schon lange vorhergesehen, dass die Nachfrage für die Produkte von Amyris exponentiell steigen würde, daher sollte es am Ende auch einige beeindruckende Zahlen zu vermelden geben. Sobald die Kosten niedrig genug sind, wird es neue Produkte geben, was die Kosten noch weiter drücken sollte und zu noch mehr Produkten führen sollte und so weiter..."
Das war zu Kursen um $1,50 rum, als der Report erschien. Emissionskurs war vor ziemlich genau 6 Jahren $16
Wer hier ausnahmsweise mal zu spät kam, wurde und wird weiterhin belohnt
Ich habe jetzt schon mehrfach nachgekauft (0,505$ / 0,552$ / 0,716$) und dabei immer wieder meinen EK verteuert und ich komme trotzdem nicht umhin festzustellen, man hat einfach immer noch zu wenig AMYRIS im Portefeuille
Schön zu sehen, wo wir Anfang 2016 standen - $3 bis Jahresende und auch fool.com hat zweifelsohne seinen prognostizierten Verdoppler.
Zitat von Oberlaendler: Damit dürfte die Verdopplung seit dem Erscheinen des Artikel erreicht sein:
Nix für ungut, aber besagter Artikel zur Threaderöffnung erschien am 04.01.2016 und hier in D eine Woche später.
Zitat:
"Amyris Eine weitere Aktie, die sich verdoppeln oder um 50 % fallen könnte ist Amyris (WKN:A1C51H). Das Biotech-Unternehmen hat sehr viel Potenzial und nutzt nach spezielle genetisch veränderte Hefen, um wertvolle Chemikalien für Kunden in verschiedenen Bereichen herzustellen, von Kosmetika bis zu Industrieprodukten und Lebensmitteln. Die Investoren haben schon lange vorhergesehen, dass die Nachfrage für die Produkte von Amyris exponentiell steigen würde, daher sollte es am Ende auch einige beeindruckende Zahlen zu vermelden geben. Sobald die Kosten niedrig genug sind, wird es neue Produkte geben, was die Kosten noch weiter drücken sollte und zu noch mehr Produkten führen sollte und so weiter..."
Das war zu Kursen um $1,50 rum, als der Report erschien. Emissionskurs war vor ziemlich genau 6 Jahren $16
Wer hier ausnahmsweise mal zu spät kam, wurde und wird weiterhin belohnt
Ich habe jetzt schon mehrfach nachgekauft (0,505$ / 0,552$ / 0,716$) und dabei immer wieder meinen EK verteuert und ich komme trotzdem nicht umhin festzustellen, man hat einfach immer noch zu wenig AMYRIS im Portefeuille
Schön zu sehen, wo wir Anfang 2016 standen - $3 bis Jahresende und auch fool.com hat zweifelsohne seinen prognostizierten Verdoppler.
Einfaches Einfügen von wallstreetONLINE Charts: So funktionierts.
Amyris Executes Definitive Collaboration Agreements with Leading Global Nutraceuticals Partner
Amyris
3 minutes ago
GlobeNewswire
EMERYVILLE, Calif., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Amyris, Inc. (AMRS), the industrial bioscience company has executed definitive agreements for its strategic partnership and financing with a global nutraceuticals market leader as previously described on September 30, 2016. These agreements include the expansion of a new nutraceutical market that is expected to represent $40-$50 million of annual revenue once developed and scaled, a related strategic investment, and an unsecured credit facility of $25 million with a five-year maturity.
“We are very pleased with the significant traction we are experiencing in the first market we launched with this partner earlier this year and the speed by which we’ve been able to execute the expanded agreement into our second nutraceutical market with this partner. We expect the second nutraceutical product to reach full scale production in 2019 and combined with our first product with this partner we expect will generate approximately $100 million annually,” said John Melo, Amyris President & CEO. “We expect 2017 revenue from the first targeted product of around $40 million.”
Continued Melo, “We are very pleased with how well our partnership business model is delivering and the strategic nature of our partners.”
The closing of the collaboration expansion and credit agreements remains subject to obtaining certain required approvals.
About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, and pharmaceuticals and nutraceuticals. More information about the company is available at www.amyris.com.
Forward-Looking Statements
This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as the expected annual revenue from the collaboration expansion once developed and scaled, the anticipated closing of the collaboration expansion and credit facility, the expected timeline to reach full scale production for the product under the collaboration expansion, and the anticipated annual revenue from all products under the partnership as well as from the first targeted product with the partner) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to manufacturing capacity at Amyris’s Brotas facility, delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris’s reliance on third parties to achieve its goals, and other risks detailed in the “Risk Factors” section of Amyris’s quarterly report on Form 10-Q filed on August 9, 2016. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.
Amyris, the Amyris logo and Biofene are registered trademarks of Amyris, Inc.
Note to Editors: Please see news release issued September 30, 2016, entitled “Amyris Expands in Global Nutraceuticals Market with New Collaboration and Partner Funding of $30 Million.”
Contact:
Contact:
Peter DeNardo
Director, Investor Relations and Corporate Communications
Amyris, Inc.
+1 (510) 740-7481
investor@amyris.com
pr@amyris.com
Amyris
3 minutes ago
GlobeNewswire
EMERYVILLE, Calif., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Amyris, Inc. (AMRS), the industrial bioscience company has executed definitive agreements for its strategic partnership and financing with a global nutraceuticals market leader as previously described on September 30, 2016. These agreements include the expansion of a new nutraceutical market that is expected to represent $40-$50 million of annual revenue once developed and scaled, a related strategic investment, and an unsecured credit facility of $25 million with a five-year maturity.
“We are very pleased with the significant traction we are experiencing in the first market we launched with this partner earlier this year and the speed by which we’ve been able to execute the expanded agreement into our second nutraceutical market with this partner. We expect the second nutraceutical product to reach full scale production in 2019 and combined with our first product with this partner we expect will generate approximately $100 million annually,” said John Melo, Amyris President & CEO. “We expect 2017 revenue from the first targeted product of around $40 million.”
Continued Melo, “We are very pleased with how well our partnership business model is delivering and the strategic nature of our partners.”
The closing of the collaboration expansion and credit agreements remains subject to obtaining certain required approvals.
About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, and pharmaceuticals and nutraceuticals. More information about the company is available at www.amyris.com.
Forward-Looking Statements
This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as the expected annual revenue from the collaboration expansion once developed and scaled, the anticipated closing of the collaboration expansion and credit facility, the expected timeline to reach full scale production for the product under the collaboration expansion, and the anticipated annual revenue from all products under the partnership as well as from the first targeted product with the partner) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to manufacturing capacity at Amyris’s Brotas facility, delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris’s reliance on third parties to achieve its goals, and other risks detailed in the “Risk Factors” section of Amyris’s quarterly report on Form 10-Q filed on August 9, 2016. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.
Amyris, the Amyris logo and Biofene are registered trademarks of Amyris, Inc.
Note to Editors: Please see news release issued September 30, 2016, entitled “Amyris Expands in Global Nutraceuticals Market with New Collaboration and Partner Funding of $30 Million.”
Contact:
Contact:
Peter DeNardo
Director, Investor Relations and Corporate Communications
Amyris, Inc.
+1 (510) 740-7481
investor@amyris.com
pr@amyris.com
BRIEF-Guanfu Holdings' unit plans to invest $5 mln in Amyris
quelle: http://www.reuters.com/article/idUSL4N1CX3OA?type=companyNew…
quelle: http://www.reuters.com/article/idUSL4N1CX3OA?type=companyNew…
gute Zusammenfassung zum aktuellen Stand, mal sehen was die Zahlen nächste Woche bringen:
http://oracledispatch.com/2016/10/28/amyris-inc-nasdaqamrs-m…
Amyris Inc (NASDAQ:AMRS) is a complex stock to say the least. Depending on the time period in question, if I asked you what Amyris (AMRS) did, it’s possible you would give me different answers. To put it simply, business model has changed over the years. In regards to today, the company is making its footprint in the bio-manufacturing industry.
What I find interesting, fifty or so years ago, there wasn’t a business model for bio-manufacturing. However, today, Amyris is one of the industry leaders, producing molecules for the cosmetic, nutraceutical, drug and rubber market(s).
Amyris Inc (NASDAQ:AMRS) is a prime example of weird and unusual industries like the bio-manufacturing market that are experiencing rapid growth. Moreover, companies like Amyris are starting to realize the growth and cash flow potential. For an example, in Q2 product sales grew almost 50%, while SG&A fell 21% Q/Q. Not only did the company have a record quarter, but they signed new collaboration agreements with Givaudan, Ginkgo Bioworks, The Bill & Melinda Gates Foundation and Janssen Biotech. It was an impressive quarter, to say the least.
The CEO had the following to say in regards to the quarter:
“We’re very pleased with reaching our best ever quarter of signing new collaborations that have already funded more than $20 million of payments this year and are expected to more than underpin our full year targets,” said John Melo, Amyris President & CEO. “We are encouraged by these results and our success in delivering on our stated milestones and goals thus far this year. Additional progress in the coming months is anticipated to further grow our customer base, improve our balance sheet and further position the company as the leader in industrial biotechnology.”
It’s hard to not get excited about the company. They are making revolutionary steps to create life-changing molecules, the company is growing at a rapid clip, huge names have signed agreements to work with the company and expenses are beginning to fall. Given my value background, the latter is the most exciting for me. If Amyris can manage to continuing cutting costs – and pull some profits in the near-term, the valuation will begin to look enticing. The company is still a tad away from cash in-flows, but the improvement in the first six months is putting the company on the right track. And for the record, free cash flow in the first six months was -$17.4 million from the -$28.8 million Y/Y.
Find out when $AMRS reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
Even though the company is making great strides, there are still a few overhangs. One of the biggest overhangs is the convertible debt on the balance sheet. This is a two-pronged overhang; giving the company a scary risk profile due to the lofty debt position and potential for real dilution if and when the debt converts. On the flip-side, there is reason to believe this debt overhang will be subdued in the near-term.
First and foremost, the company is cutting costs. Not only are costs rapidly falling, but there is operational leverage as sales increase. I like companies that can increase their margins when sales increase – Amyris is one of those companies. Likewise, the company believes it will be free cash flow positive sometime in 2017 – allowing them a better handle on the debt profile. Sure, they have stated in the past that they will be free cash flow positive in the future, which never took hold. However, the recent cost-containments and sales growth may help them hit their guidance this time.
Secondly, the company has plans to sell $40-60 million worth of assets. If and when this happens, it’s likely they will pay down their lofty debt position, putting the company in a much better risk/reward standpoint. I am not sure if they can hit this lofty goal, but if done, the risk profile will decrease. I like to think of an asset sale as a type of hidden upside for the company.
Thirdly, the majority of the long-term debt is due in 2019. If the company sells these assets, cuts costs and continues growing the top line, while becoming free cash flow positive, it’s very possible for the company to cut debt – or pay it off completely – without shareholders taking any dilution.
Finally, John Doerr recently purchased $16 million of the notes and warrants (through a private placement), allowing him to purchase 2,285,714 shares of the company’s stock. Doerr is a highly regarded venture capitalist – being an investor in Amazon and Google (on both companies’ boards). I’m not saying Doerr is always right, and the purchase was a PP rather than an open market purchase, but sometimes it’s not bad to coattail big names in the investment community.
Overall, the company looks quite attractive. They continue to sign new contracts (a new one with Ginkgo and $25 million with a nutraceutical company to be exact), profitability is around the corner and the market they serve is rather hot. With insiders owning 35% and an impressive amount of institutional owners, the investment is rather attractive. For continuing coverage on shares of $AMRS stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!
http://oracledispatch.com/2016/10/28/amyris-inc-nasdaqamrs-m…
Amyris Inc (NASDAQ:AMRS) is a complex stock to say the least. Depending on the time period in question, if I asked you what Amyris (AMRS) did, it’s possible you would give me different answers. To put it simply, business model has changed over the years. In regards to today, the company is making its footprint in the bio-manufacturing industry.
What I find interesting, fifty or so years ago, there wasn’t a business model for bio-manufacturing. However, today, Amyris is one of the industry leaders, producing molecules for the cosmetic, nutraceutical, drug and rubber market(s).
Amyris Inc (NASDAQ:AMRS) is a prime example of weird and unusual industries like the bio-manufacturing market that are experiencing rapid growth. Moreover, companies like Amyris are starting to realize the growth and cash flow potential. For an example, in Q2 product sales grew almost 50%, while SG&A fell 21% Q/Q. Not only did the company have a record quarter, but they signed new collaboration agreements with Givaudan, Ginkgo Bioworks, The Bill & Melinda Gates Foundation and Janssen Biotech. It was an impressive quarter, to say the least.
The CEO had the following to say in regards to the quarter:
“We’re very pleased with reaching our best ever quarter of signing new collaborations that have already funded more than $20 million of payments this year and are expected to more than underpin our full year targets,” said John Melo, Amyris President & CEO. “We are encouraged by these results and our success in delivering on our stated milestones and goals thus far this year. Additional progress in the coming months is anticipated to further grow our customer base, improve our balance sheet and further position the company as the leader in industrial biotechnology.”
It’s hard to not get excited about the company. They are making revolutionary steps to create life-changing molecules, the company is growing at a rapid clip, huge names have signed agreements to work with the company and expenses are beginning to fall. Given my value background, the latter is the most exciting for me. If Amyris can manage to continuing cutting costs – and pull some profits in the near-term, the valuation will begin to look enticing. The company is still a tad away from cash in-flows, but the improvement in the first six months is putting the company on the right track. And for the record, free cash flow in the first six months was -$17.4 million from the -$28.8 million Y/Y.
Find out when $AMRS reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
Even though the company is making great strides, there are still a few overhangs. One of the biggest overhangs is the convertible debt on the balance sheet. This is a two-pronged overhang; giving the company a scary risk profile due to the lofty debt position and potential for real dilution if and when the debt converts. On the flip-side, there is reason to believe this debt overhang will be subdued in the near-term.
First and foremost, the company is cutting costs. Not only are costs rapidly falling, but there is operational leverage as sales increase. I like companies that can increase their margins when sales increase – Amyris is one of those companies. Likewise, the company believes it will be free cash flow positive sometime in 2017 – allowing them a better handle on the debt profile. Sure, they have stated in the past that they will be free cash flow positive in the future, which never took hold. However, the recent cost-containments and sales growth may help them hit their guidance this time.
Secondly, the company has plans to sell $40-60 million worth of assets. If and when this happens, it’s likely they will pay down their lofty debt position, putting the company in a much better risk/reward standpoint. I am not sure if they can hit this lofty goal, but if done, the risk profile will decrease. I like to think of an asset sale as a type of hidden upside for the company.
Thirdly, the majority of the long-term debt is due in 2019. If the company sells these assets, cuts costs and continues growing the top line, while becoming free cash flow positive, it’s very possible for the company to cut debt – or pay it off completely – without shareholders taking any dilution.
Finally, John Doerr recently purchased $16 million of the notes and warrants (through a private placement), allowing him to purchase 2,285,714 shares of the company’s stock. Doerr is a highly regarded venture capitalist – being an investor in Amazon and Google (on both companies’ boards). I’m not saying Doerr is always right, and the purchase was a PP rather than an open market purchase, but sometimes it’s not bad to coattail big names in the investment community.
Overall, the company looks quite attractive. They continue to sign new contracts (a new one with Ginkgo and $25 million with a nutraceutical company to be exact), profitability is around the corner and the market they serve is rather hot. With insiders owning 35% and an impressive amount of institutional owners, the investment is rather attractive. For continuing coverage on shares of $AMRS stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!
zahlen gestern nach börsenschluss:
Q3 EPS of -$0.07 misses by $0.01.
Revenue of $26.54M (+209.0% Y/Y) misses by $7.07M.
quelle: http://seekingalpha.com/pr/16655382-amyris-reports-third-qua…
hätte mir mehr erwartet...mal sehen was der markt heute draus macht, ausblick bleibt ja weiter optimistisch
Q3 EPS of -$0.07 misses by $0.01.
Revenue of $26.54M (+209.0% Y/Y) misses by $7.07M.
quelle: http://seekingalpha.com/pr/16655382-amyris-reports-third-qua…
hätte mir mehr erwartet...mal sehen was der markt heute draus macht, ausblick bleibt ja weiter optimistisch
Amyris Achieves Key Milestone in Major Drug Discovery Collaboration
GlobeNewswire•November 16, 2016
EMERYVILLE, Calif., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Amyris, Inc. (AMRS), the industrial bioscience company, is pleased to announce that just months after initiating a collaboration with one of the world’s leading pharmaceutical companies, it has successfully achieved the first milestone under the agreement. This milestone resulted in the creation of a robust, sensitive activity assay for an oncology target in a live yeast strain. This high-throughput assay enables screening for chemical diversity found in nature using Amyris’s proprietary µPharm™ platform, with the potential to provide previously inaccessible molecule targets.
The µPharm platform combines two powerful technologies that can significantly accelerate and reduce the cost of new drug discovery. The Amyris platform is groundbreaking in its ability to design and scale molecules that are becoming disruptive workhorses across several industries. This capability is unique and allows broad access to a significant variety of naturally-evolved molecules in a rapid, high-throughput format. Active molecules can be scaled for production in yeast, further tested, and developed into market-ready pharmaceuticals at a cost and speed that the company believes has not been realized before in the pharmaceutical industry.
“We’re excited by how quickly we’ve achieved initial success in this project for one of the largest and most innovative companies in the sector,” said John Melo, Amyris President & CEO. “We believe our technology platform is well suited to efficiently drive advancements in drug discovery while meeting our partners’ unique requirements and helping to save lives. Our demonstrated capabilities have led to signing several partnership agreements with leading global pharmaceutical companies this year. We are achieving in months what these companies have been chasing for years.”
Continued Melo, “Along with more than doubling our revenue this year we are accelerating time to market for our biopharma partners. Our work to replace mammalian cells, deliver better antibiotics and discover new oncology treatments has the potential to transform drug discovery and make more available leading treatments to improve the lives of patients throughout the world.”
About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, and pharmaceuticals and nutraceuticals. More information about the company is available at www.amyris.com.
Forward-Looking Statements
This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events such as the Amyris µPharm platform technology enabling development of pharmaceuticals at a cost and speed sufficient to efficiently drive advancements in drug discovery, continued achievement of, and pace of achievement for collaboration milestones, and annual revenue expectations that involve risks and uncertainties. These statements are based on management’s current expectations and actual results and future events may differ materially due to risks and uncertainties, including the company's liquidity and ability to fund operating and capital expenses, Amyris's reliance on third parties to achieve its goals, timing and execution risks associated with development and manufacturing, potential delays or failures in development, production and commercialization of products, and other risks detailed in the “Risk Factors” section of Amyris’s quarterly report on Form 10-Q filed on November 9, 2016. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.
Amyris, the Amyris logo and µPharm are registered trademarks of Amyris, Inc
GlobeNewswire•November 16, 2016
EMERYVILLE, Calif., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Amyris, Inc. (AMRS), the industrial bioscience company, is pleased to announce that just months after initiating a collaboration with one of the world’s leading pharmaceutical companies, it has successfully achieved the first milestone under the agreement. This milestone resulted in the creation of a robust, sensitive activity assay for an oncology target in a live yeast strain. This high-throughput assay enables screening for chemical diversity found in nature using Amyris’s proprietary µPharm™ platform, with the potential to provide previously inaccessible molecule targets.
The µPharm platform combines two powerful technologies that can significantly accelerate and reduce the cost of new drug discovery. The Amyris platform is groundbreaking in its ability to design and scale molecules that are becoming disruptive workhorses across several industries. This capability is unique and allows broad access to a significant variety of naturally-evolved molecules in a rapid, high-throughput format. Active molecules can be scaled for production in yeast, further tested, and developed into market-ready pharmaceuticals at a cost and speed that the company believes has not been realized before in the pharmaceutical industry.
“We’re excited by how quickly we’ve achieved initial success in this project for one of the largest and most innovative companies in the sector,” said John Melo, Amyris President & CEO. “We believe our technology platform is well suited to efficiently drive advancements in drug discovery while meeting our partners’ unique requirements and helping to save lives. Our demonstrated capabilities have led to signing several partnership agreements with leading global pharmaceutical companies this year. We are achieving in months what these companies have been chasing for years.”
Continued Melo, “Along with more than doubling our revenue this year we are accelerating time to market for our biopharma partners. Our work to replace mammalian cells, deliver better antibiotics and discover new oncology treatments has the potential to transform drug discovery and make more available leading treatments to improve the lives of patients throughout the world.”
About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, and pharmaceuticals and nutraceuticals. More information about the company is available at www.amyris.com.
Forward-Looking Statements
This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events such as the Amyris µPharm platform technology enabling development of pharmaceuticals at a cost and speed sufficient to efficiently drive advancements in drug discovery, continued achievement of, and pace of achievement for collaboration milestones, and annual revenue expectations that involve risks and uncertainties. These statements are based on management’s current expectations and actual results and future events may differ materially due to risks and uncertainties, including the company's liquidity and ability to fund operating and capital expenses, Amyris's reliance on third parties to achieve its goals, timing and execution risks associated with development and manufacturing, potential delays or failures in development, production and commercialization of products, and other risks detailed in the “Risk Factors” section of Amyris’s quarterly report on Form 10-Q filed on November 9, 2016. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.
Amyris, the Amyris logo and µPharm are registered trademarks of Amyris, Inc
jemand ne erklärung warum maxwell hier als größter investor seit tagen so ein haufen shares raushaut?
Nur für den Fall, dass hier noch jemand mitliest:
I'm sure I'm going to love it
Liest hier noch jemand und weiß wann der Qbericht kommt?
Antwort auf Beitrag Nr.: 54.156.284 von boersehp am 24.01.17 21:24:12
Von denen, die es genau wissen, liest hier sicher keiner mit
Letztes Jahr sah es so aus:
Mar 9, 2016 - Amyris 2015 Fourth Quarter Financial Results
Zitat von boersehp: Liest hier noch jemand und weiß wann der Qbericht kommt?
Von denen, die es genau wissen, liest hier sicher keiner mit
Letztes Jahr sah es so aus:
Mar 9, 2016 - Amyris 2015 Fourth Quarter Financial Results
Antwort auf Beitrag Nr.: 54.178.247 von soulist am 27.01.17 09:45:49
Amyris to Announce Fourth Quarter and Fiscal Year 2016 Financial Results on Thursday, March 2, 2017
Zitat von soulist:Zitat von boersehp: Liest hier noch jemand und weiß wann der Qbericht kommt?
Von denen, die es genau wissen, liest hier sicher keiner mit
Letztes Jahr sah es so aus:
Mar 9, 2016 - Amyris 2015 Fourth Quarter Financial Results
Amyris to Announce Fourth Quarter and Fiscal Year 2016 Financial Results on Thursday, March 2, 2017
Tja - das Wasser steht Amyris weiterhin bis zum Hals....
http://www.fool.com/investing/2017/01/31/investors-are-betti…
http://www.fool.com/investing/2017/01/31/investors-are-betti…
Bio-Flüssigkautschuk verbessert Eis-Grip
20.02.2017
Farnesen-Flüssigkautschuk erstmalig in Winterreifen eingesetzt
http://www.kuraray.eu/presse/singleviewnews/news/bio-fluessi…
LFR Eigenschaften:
Dieser firmeneigene Flüssigkautschuk beinhaltet Farnesen, das durch Fermentation aus Zuckerrohr gewonnen wird. Die Viskosität ist im Vergleich zu konventionellen Flüssigkautschuken geringer. Eigesetzt als Additiv verleiht es Kautschukmischungen eine hohe Plastizität. Darüber hinaus behält es selbst bei niedrigen Temperaturen hohe Elastizität und verbessert die Rutschfestigkeit auf Eis. Aufgrund seines optimalen Molekulargewichts reagiert LFR beim Vulkanisieren vollständig mit festem Kautschuk. Dadurch bleibt es anders als Öl, das mit der Zeit an die Gummioberfläche wandert und damit die Härte verringert, im Gummi eingebunden. Somit bleibt auch die Rutschfestigkeit über einen langen Zeitraum erhalten.
Über Amyris, Inc.:
Amyris (Nasdaq:AMRS) ist das intergierte Unternehmen für nachwachsende Produkte, das weltweit führenden Marken nachhaltiges Wachstum ermöglicht. Amyris setzt seine innovativen Lösungen ein, um pflanzliche Zucker in Kohlenwasserstoffmoleküle zu überführen und Spezialitäten-Ingredienzien und Endverbraucherprodukte herzustellen. Das Unternehmen beliefert eine Vielzahl von Märkten mit seinen “No Compromise®“ Produkten, darunter chemische Spezialitäten und Hochleistungschemikalien, Geschmacks- und Duftstoffe, Kosmetikinhaltsstoffe, Pharmazeutika und Nahrungsergänzungsmittel ("Nutraceuticals").
20.02.2017
Farnesen-Flüssigkautschuk erstmalig in Winterreifen eingesetzt
http://www.kuraray.eu/presse/singleviewnews/news/bio-fluessi…
LFR Eigenschaften:
Dieser firmeneigene Flüssigkautschuk beinhaltet Farnesen, das durch Fermentation aus Zuckerrohr gewonnen wird. Die Viskosität ist im Vergleich zu konventionellen Flüssigkautschuken geringer. Eigesetzt als Additiv verleiht es Kautschukmischungen eine hohe Plastizität. Darüber hinaus behält es selbst bei niedrigen Temperaturen hohe Elastizität und verbessert die Rutschfestigkeit auf Eis. Aufgrund seines optimalen Molekulargewichts reagiert LFR beim Vulkanisieren vollständig mit festem Kautschuk. Dadurch bleibt es anders als Öl, das mit der Zeit an die Gummioberfläche wandert und damit die Härte verringert, im Gummi eingebunden. Somit bleibt auch die Rutschfestigkeit über einen langen Zeitraum erhalten.
Über Amyris, Inc.:
Amyris (Nasdaq:AMRS) ist das intergierte Unternehmen für nachwachsende Produkte, das weltweit führenden Marken nachhaltiges Wachstum ermöglicht. Amyris setzt seine innovativen Lösungen ein, um pflanzliche Zucker in Kohlenwasserstoffmoleküle zu überführen und Spezialitäten-Ingredienzien und Endverbraucherprodukte herzustellen. Das Unternehmen beliefert eine Vielzahl von Märkten mit seinen “No Compromise®“ Produkten, darunter chemische Spezialitäten und Hochleistungschemikalien, Geschmacks- und Duftstoffe, Kosmetikinhaltsstoffe, Pharmazeutika und Nahrungsergänzungsmittel ("Nutraceuticals").
Antwort auf Beitrag Nr.: 54.213.460 von Mittachmahl am 01.02.17 13:40:56
Ja klar
Zitat von Mittachmahl: Tja - das Wasser steht Amyris weiterhin bis zum Hals....
Ja klar
Gehts auch ein bisschen substantiierter? Ich meine, mehr als bunte Smileys und John Melos Märchenstunde.
Vielleicht kannst Du ja mal erklären, wie die Firma gedenkt mehr als U$ 1bn accrued deficit wieder reinzuholen.
Ist ja nicht umsonst ein Pennystock geworden.....
Vielleicht kannst Du ja mal erklären, wie die Firma gedenkt mehr als U$ 1bn accrued deficit wieder reinzuholen.
Ist ja nicht umsonst ein Pennystock geworden.....
Antwort auf Beitrag Nr.: 54.370.414 von Mittachmahl am 21.02.17 11:09:17zahlen gestern mal wieder eine einzige enttäuschung, melo wiederholt sich...
verlust höher als erlöse...dazu die massive dilution im letzten jahr und mit jedem quartalsbericht weitere versprechungen, die mit dem folgenden quartalsbericht dann wieder nicht gehalten werden
dazu haut temasek seit monaten aktien auf den markt ohne wirkliche kurspflege...ich vermute, wir sehen hier im laufe des jahres beim kurs neue tiefstände - leider
verlust höher als erlöse...dazu die massive dilution im letzten jahr und mit jedem quartalsbericht weitere versprechungen, die mit dem folgenden quartalsbericht dann wieder nicht gehalten werden
dazu haut temasek seit monaten aktien auf den markt ohne wirkliche kurspflege...ich vermute, wir sehen hier im laufe des jahres beim kurs neue tiefstände - leider
6 APRIL 2017 BY SATPRNEWS
Synthetic Biology Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016-2024
"...Key players operating in the synthetic biology market include DuPont, Amyris, Inc., GenScript USA Inc., Integrated DNA Technologies, Intrexon Corporation, New England Biolabs, Inc., Thermo Fisher Scientific, Inc., Synthetic Genomics, Inc., Royal DSM, and Novozymes..."
http://www.military-technologies.net/2017/04/06/synthetic-bi…
Als 2. "Key player" nach DuPont genannt zu werden, hat was
Synthetic Biology Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016-2024
"...Key players operating in the synthetic biology market include DuPont, Amyris, Inc., GenScript USA Inc., Integrated DNA Technologies, Intrexon Corporation, New England Biolabs, Inc., Thermo Fisher Scientific, Inc., Synthetic Genomics, Inc., Royal DSM, and Novozymes..."
http://www.military-technologies.net/2017/04/06/synthetic-bi…
Als 2. "Key player" nach DuPont genannt zu werden, hat was
so, nachdem temasek nun offensichtlich durch ist und keine shares mehr auf den markt haut, zeit sich den fundamentalen daten der aktie zu widmen:
Amyris's Biossance Delivers Record First-Quarter Sales — #1 Eye Product at Sephora and On Track for Much Better than Expected 2017
http://investors.amyris.com/releasedetail.cfm?ReleaseID=1021…
Amyris's Biossance Delivers Record First-Quarter Sales — #1 Eye Product at Sephora and On Track for Much Better than Expected 2017
http://investors.amyris.com/releasedetail.cfm?ReleaseID=1021…
und charttechnisch hat sich seit gestern der wind gedreht:
http://scalpthatstock.com/amyris-inc-amrs-stock-chart-techni…
http://scalpthatstock.com/amyris-inc-amrs-stock-chart-techni…
was mich wundert ist, dass AMRS in europa so dermaßen unter dem radar läuft, aber vielleicht ändert sich das ja dann in 2017 doch noch und ceo melo kann sich ende 2017 dann doch noch an seinen prognosen messen lassen bzw. AMRS kommt an den punkt, wo versprechungen eingehalten werden...mittelfristig ist das potenzial jedenfalls riesig auch wenn die verschuldungssituation kurzfristig ein risiko bleibt
Antwort auf Beitrag Nr.: 54.733.323 von ice_05 am 13.04.17 14:56:37
Peanuts, das ist a la long eine xx Mrd-Dollar Company
Happy Yeastern
Zitat von ice_05: ..mittelfristig ist das potenzial jedenfalls riesig auch wenn die verschuldungssituation kurzfristig ein risiko bleibt
Peanuts, das ist a la long eine xx Mrd-Dollar Company
Happy Yeastern
Antwort auf Beitrag Nr.: 54.735.456 von soulist am 13.04.17 19:33:33na ja...bis dahin ist es noch ein weiter weg...wenn wir hier ende 2017 bei 1,40 usd sind, bin ich es zufrieden...geduld ist angesagt, zumal temasek noch auf rund 50 mio aktien sitzt...
falls hier noch andere mitlesen und interessiert sind, der hier hat geschichte und potenzial im dezember sehr schön zusammengefasst:
Amyris, Inc. (NASDAQ:AMRS) 200% To 300% Near-Term Upside. North Of $5.00 In 2017
https://seekingalpha.com/instablog/48005763-oxonian/4941971-…" target="_blank" rel="nofollow ugc noopener">
https://seekingalpha.com/instablog/48005763-oxonian/4941971-…
Amyris, Inc. (NASDAQ:AMRS) 200% To 300% Near-Term Upside. North Of $5.00 In 2017
https://seekingalpha.com/instablog/48005763-oxonian/4941971-…" target="_blank" rel="nofollow ugc noopener">
https://seekingalpha.com/instablog/48005763-oxonian/4941971-…
Antwort auf Beitrag Nr.: 54.742.731 von ice_05 am 15.04.17 21:51:17
Sag mal ice, hat der Cherry sich ein Apple-Logo auf seinen Dell geklebt? (ca ab 1:10)
Zitat von ice_05: und hier noch etwas zum potenzial:
http://www.bbc.com/specialfeatures/horizonsbusiness/seriessi…
Sag mal ice, hat der Cherry sich ein Apple-Logo auf seinen Dell geklebt? (ca ab 1:10)
Antwort auf Beitrag Nr.: 54.744.586 von soulist am 16.04.17 17:52:38 hat er...ich hoffe sie verarschen uns mit amrs nicht so
hat er...ich hoffe sie verarschen uns mit amrs nicht so
Antwort auf Beitrag Nr.: 54.745.243 von ice_05 am 16.04.17 22:51:40
Oh ja, ich werde wohl vorsichtshalber mein Verkaufslimit von 60 $ auf 57 $ herabsetzen - sicher ist sicher
Zitat von ice_05:
Oh ja, ich werde wohl vorsichtshalber mein Verkaufslimit von 60 $ auf 57 $ herabsetzen - sicher ist sicher
Antwort auf Beitrag Nr.: 54.747.142 von soulist am 17.04.17 14:17:40da bin ich konservativer...4,80 usd geht bei mir alles raus...da stehen meine auch schon seit monaten im ask...
Antwort auf Beitrag Nr.: 54.747.142 von soulist am 17.04.17 14:17:40je nachdem wie hoch der r/s ausfallen wird, könnten deine 57 usd dann doch schneller kommen als gedacht
morgen gibt es hier einen schönen pullback...
morgen gibt es hier einen schönen pullback...
Antwort auf Beitrag Nr.: 54.749.104 von ice_05 am 17.04.17 23:38:47
Sag ich doch
Drüben drehen die am Rad, aber echt eine Meldung zur Unzeit, wir waren doch sehr gut unterwegs Richtung Dollar-Marke...
Zitat von ice_05: je nachdem wie hoch der r/s ausfallen wird, könnten deine 57 usd dann doch schneller kommen als gedacht
morgen gibt es hier einen schönen pullback...
Sag ich doch
Drüben drehen die am Rad, aber echt eine Meldung zur Unzeit, wir waren doch sehr gut unterwegs Richtung Dollar-Marke...
Antwort auf Beitrag Nr.: 54.749.434 von soulist am 18.04.17 07:47:16ja, melo ist und bleibt eine pfeife als ceo - der hat es einfach raus, wie man anlegerkapital vernichtet...
drüben nutzt man solche filings natürlich, um auch wirklich jede sau durch´s dorf zu treiben, bis hin zur wieder aufflammenden ch11 diskussion...
auch wenn man im AH im vergleich zum tagesumsatz gestern nur mit einem bruchteil der tagesgehandelten shares das ding um 25% in den boden gestampft hat, traue ich der aktie heute weitere abschläge zu...zurück auf los in die "mittvierziger"
drüben nutzt man solche filings natürlich, um auch wirklich jede sau durch´s dorf zu treiben, bis hin zur wieder aufflammenden ch11 diskussion...
auch wenn man im AH im vergleich zum tagesumsatz gestern nur mit einem bruchteil der tagesgehandelten shares das ding um 25% in den boden gestampft hat, traue ich der aktie heute weitere abschläge zu...zurück auf los in die "mittvierziger"
Antwort auf Beitrag Nr.: 54.750.841 von ice_05 am 18.04.17 11:16:46
Vielleicht hilft das dabei
pelvis auf ST: It seems from the 10k that they will be loosing money during whole 2017,they have no money to built Brotas2 or to pay interest
Like seriously, no hint in the 10k that they see a light at the end of tunnel ...
Zitat von ice_05: ...traue ich der aktie heute weitere abschläge zu...zurück auf los in die "mittvierziger"
Vielleicht hilft das dabei
pelvis auf ST: It seems from the 10k that they will be loosing money during whole 2017,they have no money to built Brotas2 or to pay interest
Like seriously, no hint in the 10k that they see a light at the end of tunnel ...
Antwort auf Beitrag Nr.: 54.751.534 von soulist am 18.04.17 12:53:59
War irgendwie klar, hab 3k PTX verkauft um vll noch 20k bei 0,51EUR Amy abzufischen - also kein stinky bid, war gar nicht unverschämt - aber war trotzdem nix zu machen. Alles gut informierte Investoren hier
Mal sehen was der Tag noch bringt, ich setz jetzt auf Clay Trader und seine W..
Zitat von ice_05: ...traue ich der aktie heute weitere abschläge zu...zurück auf los in die "mittvierziger"
War irgendwie klar, hab 3k PTX verkauft um vll noch 20k bei 0,51EUR Amy abzufischen - also kein stinky bid, war gar nicht unverschämt - aber war trotzdem nix zu machen. Alles gut informierte Investoren hier
Mal sehen was der Tag noch bringt, ich setz jetzt auf Clay Trader und seine W..
Antwort auf Beitrag Nr.: 54.752.434 von soulist am 18.04.17 15:08:29claytrader und ST - darauf kann man sich blind verlassen
mal sehen wo wir heute abend stehen und mit was uns melo die nächsten tage und wochen noch überrascht...grundsätzlich halte ich einen r/s über kurz oder lang hier sogar für zwingend erforderlich um der zockerei ein ende zu setzen
mal sehen wo wir heute abend stehen und mit was uns melo die nächsten tage und wochen noch überrascht...grundsätzlich halte ich einen r/s über kurz oder lang hier sogar für zwingend erforderlich um der zockerei ein ende zu setzen
tja - ankündigungen alleine reichen halt nicht...so lange melo nur groß im ankündigen ist und er einen solch toxischen aktionär wie temasek im boot sitzen hat, wird es in der gesamtsumme kurz- bis mittelfristig weiter nach unten gehen...
Die Verkäufe gehen weiter. Temasek hat noch einmal 1,5mio Aktien auf den Markt geworfen.
In dem Takt sind sie ca. August 2018 aus Amyris raus und ab ca. Dezember 2017 nicht mehr meldepflichtig. (unter 10%) Dann wird das intransparent.
Mal sehen ob und wann der nächste Ankeraktionär die Reissleine zieht.
M_K
In dem Takt sind sie ca. August 2018 aus Amyris raus und ab ca. Dezember 2017 nicht mehr meldepflichtig. (unter 10%) Dann wird das intransparent.
Mal sehen ob und wann der nächste Ankeraktionär die Reissleine zieht.
M_K
Nachtrag:
Am 19.4.2017 noch mal 338.864 Aktien verkauft.
M_K
Am 19.4.2017 noch mal 338.864 Aktien verkauft.
M_K
Antwort auf Beitrag Nr.: 54.774.844 von Mittachmahl am 21.04.17 13:43:40na ja, temasek in diesem zusammenhang als "ankeraktionär" zu bezeichnen? da solltest du dich etwas genauer mit deren geschichte in den letzten monaten beschäftigen...
die hauen hier ja keine aktien im klassischen sinne raus...und weil das so ist, tut das auch keiner der tatsächlichen "anker"aktionäre...temasek ist der einzige der raushaut...bleibt trotzdem die frage, warum offensichtlich keiner der übrigen "insider" davon etwas aufnimmt....das wird scheinbar, zumindest nach den aktuellen zahlen, irgendwo von kleinaktionären und zockern aufgenommen
hier sehe ich auch eines der "haare in der suppe"... und glaube daher auch an einen zeitnahen r/s
die hauen hier ja keine aktien im klassischen sinne raus...und weil das so ist, tut das auch keiner der tatsächlichen "anker"aktionäre...temasek ist der einzige der raushaut...bleibt trotzdem die frage, warum offensichtlich keiner der übrigen "insider" davon etwas aufnimmt....das wird scheinbar, zumindest nach den aktuellen zahlen, irgendwo von kleinaktionären und zockern aufgenommen
hier sehe ich auch eines der "haare in der suppe"... und glaube daher auch an einen zeitnahen r/s
Tja - wie auch immer - Temasek hin oder her:
Sie haben zur HV eingeladen und auf der Tagesordnung steht unter anderem das Kapital der Gesellschaft von 500mio Aktien auf 250mio herabzusetzen und einen split von 15:1 vorzunehmen.
https://seekingalpha.com/filing/3518794
MM
Sie haben zur HV eingeladen und auf der Tagesordnung steht unter anderem das Kapital der Gesellschaft von 500mio Aktien auf 250mio herabzusetzen und einen split von 15:1 vorzunehmen.
https://seekingalpha.com/filing/3518794
MM
Nachtrag:
Der Split wurde wohl ausgelöst durch eine NASDAQ notice vom 19.12.2016, nach dem Amyris die Listing Voraussetzungen an der NASDAQ nicht mehr erfüllt:
=> closing price below U$ 1 for 30 consecutive days...
Der Split wurde wohl ausgelöst durch eine NASDAQ notice vom 19.12.2016, nach dem Amyris die Listing Voraussetzungen an der NASDAQ nicht mehr erfüllt:
=> closing price below U$ 1 for 30 consecutive days...
Antwort auf Beitrag Nr.: 54.825.631 von Mittachmahl am 28.04.17 08:35:19und was ist an einem split in dieser konstellation so schlimm? so lange sie dabei nicht weiter verwässern, sehe ich einen solchen schritt bei der aktuellen sharezahl über kurz oder lang sogar als zwingend erforderlich an...und im übrigen musst du schon genauer lesen...sie behalten sich diesen schritt zunächst vor, sollten bis zum datum x die listing voraussetzungen nicht erfüllt werden (wobei ich unabhängig davon glaube, das der schritt kommen wird)
Amyris Announces Key Advancements Under DARPA Multi-Year Technology Investment Agreement – Enables Development of Industrial-Scale Fermentation Process For Virtually Any Biological Molecule
GlobeNewswire•May 2, 2017
EMERYVILLE, Calif., May 02, 2017 (GLOBE NEWSWIRE) -- Amyris, Inc. (AMRS), the industrial bioscience company, today announced that it has successfully expanded its world-class expertise in strain engineering and optimization to 26 key metabolic precursors across multiple organisms, as part of its Technology Investment Agreement (TIA) with the Defense Advanced Research Projects Agency (DARPA). The multi-year TIA, worth up to $35 million to create new research and development tools and technologies to significantly reduce the time and cost of bringing new molecules to market, was previously announced on September 23, 2015, as part of DARPA’s Living Foundries program.
The development and optimization of metabolic networks to these 26 metabolic intermediates and many different pathways beyond terpenoids allows Amyris to develop an industrial-scale fermentation process for virtually any biological molecule. In addition to the expansion of the range of metabolic precursors, Amyris has also successfully expanded its industry-leading high-throughput S. cerevisiae strain construction and testing pipeline to several other industrially-relevant organisms.
These advancements have the cumulative effect of drastically reducing the R&D costs and timelines for developing a commercial process for any biological target, irrespective of the final application of the molecule. This is empowering Amyris with additional resources to develop next-generation capabilities to further advance its competitive position and accelerate its capabilities to produce go-to-market sustainable supply solutions at industrial scale for its partners.
“The DARPA-funded TIA has allowed us to continue our pioneering efforts at applying automation, next-generation analytics, and machine learning algorithms to find biological solutions to the bio-manufacturing sector,” said John Melo, Amyris President and CEO. “Amyris has always been at the forefront of utilizing big-data analytics and cutting-edge tools in the biotechnology sector, and our recent R&D results continue to pave the way toward expanding our footprint in multiple markets where fermentation-derived products offer our partners and consumers a sustainable, scalable source of supply.”
About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com.
Forward-Looking Statements
This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as Amyris’s expected ability to develop an industrial-scale fermentation process for virtually any biological molecule, the anticipated reduction of R&D costs and timelines for developing a commercial process for any biological target, the expected development of next-generation capabilities, the anticipated advancement of Amyris’s competitive position, the expected acceleration of Amyris’s capabilities to produce go-to-market sustainable supply solutions at industrial scale, and Amyris’s anticipated market expansion) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to manufacturing capacity at Amyris’s Brotas facility, delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris’s reliance on third parties to achieve its goals, and other risks detailed in the “Risk Factors” section of Amyris’s annual report on Form 10-K filed on April 17, 2017. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.
GlobeNewswire•May 2, 2017
EMERYVILLE, Calif., May 02, 2017 (GLOBE NEWSWIRE) -- Amyris, Inc. (AMRS), the industrial bioscience company, today announced that it has successfully expanded its world-class expertise in strain engineering and optimization to 26 key metabolic precursors across multiple organisms, as part of its Technology Investment Agreement (TIA) with the Defense Advanced Research Projects Agency (DARPA). The multi-year TIA, worth up to $35 million to create new research and development tools and technologies to significantly reduce the time and cost of bringing new molecules to market, was previously announced on September 23, 2015, as part of DARPA’s Living Foundries program.
The development and optimization of metabolic networks to these 26 metabolic intermediates and many different pathways beyond terpenoids allows Amyris to develop an industrial-scale fermentation process for virtually any biological molecule. In addition to the expansion of the range of metabolic precursors, Amyris has also successfully expanded its industry-leading high-throughput S. cerevisiae strain construction and testing pipeline to several other industrially-relevant organisms.
These advancements have the cumulative effect of drastically reducing the R&D costs and timelines for developing a commercial process for any biological target, irrespective of the final application of the molecule. This is empowering Amyris with additional resources to develop next-generation capabilities to further advance its competitive position and accelerate its capabilities to produce go-to-market sustainable supply solutions at industrial scale for its partners.
“The DARPA-funded TIA has allowed us to continue our pioneering efforts at applying automation, next-generation analytics, and machine learning algorithms to find biological solutions to the bio-manufacturing sector,” said John Melo, Amyris President and CEO. “Amyris has always been at the forefront of utilizing big-data analytics and cutting-edge tools in the biotechnology sector, and our recent R&D results continue to pave the way toward expanding our footprint in multiple markets where fermentation-derived products offer our partners and consumers a sustainable, scalable source of supply.”
About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com.
Forward-Looking Statements
This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as Amyris’s expected ability to develop an industrial-scale fermentation process for virtually any biological molecule, the anticipated reduction of R&D costs and timelines for developing a commercial process for any biological target, the expected development of next-generation capabilities, the anticipated advancement of Amyris’s competitive position, the expected acceleration of Amyris’s capabilities to produce go-to-market sustainable supply solutions at industrial scale, and Amyris’s anticipated market expansion) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to manufacturing capacity at Amyris’s Brotas facility, delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris’s reliance on third parties to achieve its goals, and other risks detailed in the “Risk Factors” section of Amyris’s annual report on Form 10-K filed on April 17, 2017. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.
Antwort auf Beitrag Nr.: 54.846.166 von zocker1564 am 02.05.17 14:08:15das sind in meinen augen reine (wiederaufgewärmte) pr-news, wo ich nicht wirklich einzuschätzen vermag, was melo damit bezweckt.
und leider immer wieder bei amrs so gesehen die letzten monate. wenn es dann zu den quartalszahlen substanziell werden muss, enttäuschen sie wiederholt auf ganzer linie - verbunden mit der hohen anzahl an shares/temasek fällt es den shortern dann leicht, den kurs jedes mal zurückzuholen...gestern alleine 70% auf der shortseite.
hier ist vermutlich weiterhin viel geduld angesagt, wo ich doch vor ein paar wochen schon mal etwas optimistischer war...
und leider immer wieder bei amrs so gesehen die letzten monate. wenn es dann zu den quartalszahlen substanziell werden muss, enttäuschen sie wiederholt auf ganzer linie - verbunden mit der hohen anzahl an shares/temasek fällt es den shortern dann leicht, den kurs jedes mal zurückzuholen...gestern alleine 70% auf der shortseite.
hier ist vermutlich weiterhin viel geduld angesagt, wo ich doch vor ein paar wochen schon mal etwas optimistischer war...
Da sind sie, die Kapitalmassnahmen
8k und Prospektus
MM
8k und Prospektus
MM
Antwort auf Beitrag Nr.: 54.893.162 von Mittachmahl am 08.05.17 18:46:52jupp - so sieht es leider aus, auf melo ist eben "verlass", dazu braucht er noch nicht mal shareholder meeting...hatte es nach den pseudomeldungen der letzten woche schon vermutet, dass da wieder eine überraschung kommt...jetzt kommenden montag noch enttäuschende q1 zahlen und auf geht es zu neuen atl´s...
und die meldungen lesen sich wie immer:
“We are very pleased with the support of our existing shareholders and we are excited to welcome DSM as one of our newest investors and a key shareholder,” said John Melo...na dann...weiter aktionärsgeld als großzügige spende für die forschung
und die meldungen lesen sich wie immer:
“We are very pleased with the support of our existing shareholders and we are excited to welcome DSM as one of our newest investors and a key shareholder,” said John Melo...na dann...weiter aktionärsgeld als großzügige spende für die forschung
Jubelmeldungen gestern nach Börsenschluss nach Veröffentlichung der Q1 2017 Zahlen.
Amyris weiterhin tiefrot und nochmal ausgeweiteten negativen Cash Flow.
Mit einem Restbestand an cash von ~U$1,3mn in der Kasse wären ohne Kapitalmaßnahmen im Laufe des Q2 2017 die Lichter ausgegangen.
M_K
Amyris weiterhin tiefrot und nochmal ausgeweiteten negativen Cash Flow.
Mit einem Restbestand an cash von ~U$1,3mn in der Kasse wären ohne Kapitalmaßnahmen im Laufe des Q2 2017 die Lichter ausgegangen.
M_K
Antwort auf Beitrag Nr.: 54.951.245 von Mittachmahl am 16.05.17 09:02:57ein klassicher melo eben - im CC wieder blumig und rosarot die zukunft an die wand gepinselt, dumm nur dass die anleger mittlerweile wissen das AMRS die ziele nicht erreicht...
den kurs wird das tief in die 20iger bringen und als nächstes highlight sehen wir den dann den avisierten r/s
den kurs wird das tief in die 20iger bringen und als nächstes highlight sehen wir den dann den avisierten r/s
außerdem sehen wir das alle viel zu skeptisch...
Melo says: "...Amyis is in best financial position since IPO..."
während der Kurs heute ein neues ATL ansteuert
Melo says: "...Amyis is in best financial position since IPO..."
während der Kurs heute ein neues ATL ansteuert
r/s kommt mit 1:15...darf man gespannt sein, zu welchem kurs der cut kommt...
die aktie zeigt mal wieder schön...traue keinem CEO und seinen leeren versprechen, insbesondere dann nicht, wenn er ein liebhaber von schönen vielen warrants ist...
wenn es in dem tempo weitergehtm, steht die aktie bei 0,10 usd minus x und er wird mit seinem 1:15 r/s gerade so über den dollar kommen
spätestens morgen sind die 0,25 usd geschichte...
wenn es in dem tempo weitergehtm, steht die aktie bei 0,10 usd minus x und er wird mit seinem 1:15 r/s gerade so über den dollar kommen
spätestens morgen sind die 0,25 usd geschichte...
Allen Vorschlägen der Verwaltung wurden am 25.5.2017 auf der HV der Amyris zugestimmt:
http://files.shareholder.com/downloads/ABEA-4QL2IU/456658484…
Wichtig:
Punkt 6: Split kommt 15:1
Punkt 7: Reduzierung der Anzahl autorisierter Aktien von 500k auf 250k
http://files.shareholder.com/downloads/ABEA-4QL2IU/456658484…
Wichtig:
Punkt 6: Split kommt 15:1
Punkt 7: Reduzierung der Anzahl autorisierter Aktien von 500k auf 250k
Antwort auf Beitrag Nr.: 55.055.266 von Mittachmahl am 01.06.17 08:40:46http://www.nasdaqtrader.com/TraderNews.aspx?id=ETA2017-125
morgen vollzug...splitbereinigt 3,30 usd nachdem sie das teil heute noch fast auf atl geprügelt haben
morgen vollzug...splitbereinigt 3,30 usd nachdem sie das teil heute noch fast auf atl geprügelt haben
Antwort auf Beitrag Nr.: 55.084.129 von ice_05 am 05.06.17 22:19:35
Jemand bei Consors?
Sieht gut aus
PS: Zumindest so lange die Stückzahl nicht angepasst wurde
Zitat von ice_05: http://www.nasdaqtrader.com/TraderNews.aspx?id=ETA2017-125
morgen vollzug...splitbereinigt 3,30 usd nachdem sie das teil heute noch fast auf atl geprügelt haben
Jemand bei Consors?
Sieht gut aus
PS: Zumindest so lange die Stückzahl nicht angepasst wurde
der "ceo of the year" haut direkt vorm r/s noch ein paar aktien raus, konnte einfach nicht warten auf die von ihm versprochene steigerung des shareholdervalues direkt nach dem r/s
https://fintel.io/n/us/amrs
und die nächste warrant tranche scharrt auch schon mit den füssen, kurs fällt seit monaten wie ein stein - mk steigt proportional dazu
heute dann splitbereinigt im 0,10er usd bereich...läuft bei melo
https://fintel.io/n/us/amrs
und die nächste warrant tranche scharrt auch schon mit den füssen, kurs fällt seit monaten wie ein stein - mk steigt proportional dazu
heute dann splitbereinigt im 0,10er usd bereich...läuft bei melo
Den Thread könnte man mal an die neue WKN hängen, dann würde er nicht absterben. 
Letzten beide Handelstage an der NASDAQ richtig blutig. Donnerstag kommen die Zahlen zu Q2 2017. Da wissen sicher wieder ein paar mehr und setzen darauf dass Melo wiederum nicht liefert.....
MM
Letzten beide Handelstage an der NASDAQ richtig blutig. Donnerstag kommen die Zahlen zu Q2 2017. Da wissen sicher wieder ein paar mehr und setzen darauf dass Melo wiederum nicht liefert.....
MM
Antwort auf Beitrag Nr.: 55.477.473 von Mittachmahl am 08.08.17 09:23:49und heute geht es blutig weiter
short´s auch immer weiter rauf die letzten tage - ich denke melo wird die jungs am donnerstag wieder nicht enttäuschen...dsm und vivo schön abgesichert mit den vielen schönen warrant´s
dilution und schöne pr news ist das einzige was melo kann - leider...
short´s auch immer weiter rauf die letzten tage - ich denke melo wird die jungs am donnerstag wieder nicht enttäuschen...dsm und vivo schön abgesichert mit den vielen schönen warrant´s
dilution und schöne pr news ist das einzige was melo kann - leider...
Und nochmal -10% an der NASDAQ gestern pre-Q2 2017 reporting heute. DA konnte auch die lausige PR von gestern nichts reissen.....
http://investors.amyris.com/releasedetail.cfm?ReleaseID=1036…
Das waren dann mal schlanke fast 40% Market Cap. vernichtet innerhalb von 5 Handelstagen.
MM
http://investors.amyris.com/releasedetail.cfm?ReleaseID=1036…
Das waren dann mal schlanke fast 40% Market Cap. vernichtet innerhalb von 5 Handelstagen.
MM
Antwort auf Beitrag Nr.: 55.494.081 von Mittachmahl am 10.08.17 08:21:38"...As a result, later this week we will report one of our best revenue quarters in the company's history since exiting the renewable fuels business."
feinstes PR-Sprech...on of our...das kann heute nur weiter abkacken, wenn Melo hält was er "verspricht" ist die 1 vor´m Komma bis zum Wochenende wohl realistisch...leider....sicher gute forschung aber ein unfähiges mgmt. wie so oft bei solchen klitschen, das einzige was dei können ist dilution und DSM muss nur noch lang genug still halten bis sie für umsonst zugreifen können
feinstes PR-Sprech...on of our...das kann heute nur weiter abkacken, wenn Melo hält was er "verspricht" ist die 1 vor´m Komma bis zum Wochenende wohl realistisch...leider....sicher gute forschung aber ein unfähiges mgmt. wie so oft bei solchen klitschen, das einzige was dei können ist dilution und DSM muss nur noch lang genug still halten bis sie für umsonst zugreifen können
Antwort auf Beitrag Nr.: 55.497.363 von ice_05 am 10.08.17 14:15:15nächstes ATL bei 2,21 usd...ein einziges warrant/dilution desaster...
fast 50% wertverlust in knapp 2 wochen
fast 50% wertverlust in knapp 2 wochen
Antwort auf Beitrag Nr.: 55.539.876 von ice_05 am 16.08.17 22:18:18
auch wenn der resplit und der deal mit den investoren für die altaktionäre bitter - wirklich bitter - ist, ist man damit erstmal schlimmerem entkommen. amyris stellt auf dem jetzigen niveau eine aus meiner sicht hervorragende einstiegschance dar. operativ ist man richtig gut aufgestellt - etwas besser durchfinanziert ... usw.
der jüngste kursverfall
ist glaube ich eher auf börsenpsychologie und rumgeshorte zurückzuführen. auch wenn der resplit und der deal mit den investoren für die altaktionäre bitter - wirklich bitter - ist, ist man damit erstmal schlimmerem entkommen. amyris stellt auf dem jetzigen niveau eine aus meiner sicht hervorragende einstiegschance dar. operativ ist man richtig gut aufgestellt - etwas besser durchfinanziert ... usw.
Antwort auf Beitrag Nr.: 55.566.307 von derrest am 21.08.17 11:52:13
Long Term Growth Trend
How To Play This Stock
HOW TO PLAY THIS - IMO
If You Think Back Two Years, We All Have Had Those Stocks
That We Should Have Hung On To And Played On The Way Up.
Well, Two Years From Now This Will Be One Of Those Stocks.
This Is A $20 To $30 Stock In My Opinion. At Least $15 Anyway.
But Nothing Goes Straight Up. And That's Good, Because This
Is One To Nurture On The Way Up. Keep A 50% Core Position
In Case You Screw Up. Play The Technicals On The Rest To
Increase Your Position, While Skimming Profit Off The Top
To Satisfy Your Own Personal Goals.
No Need To Pump Or Bash This Either To Create The Action.
This Is The Real Deal... Ignore The Kids Stuff. There Are Plenty
Of Traders That Will Create It's Own Action. Basically, This Is
On Auto-Pilot And Is Heading Into A Long & Strong Uptrend.
Keep The Board Melo And Real. There Is No Reason To Go
Over The Edge On Pumping Or Bashing. Just Play The Hole.
Walk Softly And Carry A Big Stick... This Is A Good One.
........................................................................
IMPROVED FACTORS
1) Revenues Increased To Almost $26M
* Second Best In Company's History
2) Gross Margins Then Jumped To 33%
* Second Best In Company's History
3) Pre-Split EPS = ($0.03) ---> 10 Cents Better
The Post-Split EPS Number Equals ($0.46)
Which Beat The Analyst Estimates Of ($1.23)
That Estimate Was Beat By 77 Cents, Or 63%
* The Best EPS In The Company's History
EMBEDDED REVENUE STREAMS
This Company Is Weaving A Global Web
Which Is Supplying A Proprietary Game
Changing And Disruptive Technology Of
New Foundational Building Blocks For
1000's Of Compounds & Products On A
World Class Scale, Including Big Pharma.
Major Companies Are Willing To Collaborate
To Reduce Their Costs, While Allowing To
Share Their Future Billions In Profits.
........................................................................
2016 TOTAL ACTUAL REVENUES
Product $26M + Collabs $41M = $67M
2017 TOTAL REVENUE ESTIMATES
Product $60M + Collabs $55M = $115M
2018 PRODUCT REV SET TO DOUBLE
Plus More & Better Collabs And Catalysts
Product $130M + Other $70M = $200M ???
HEADING INTO GROWTH
Product Revenues Are Starting To Ramp Up.
Gross Margins Are Stabilizing And Improving.
EPS And EBITDA Are Heading To Breakeven.
More And Better Collaborations On The Way.
Total Costs & OpEx Will Adjust With Growth.
JMO
zusammenfassung aus us-board
EYE OF THE NEEDLELong Term Growth Trend
How To Play This Stock
HOW TO PLAY THIS - IMO
If You Think Back Two Years, We All Have Had Those Stocks
That We Should Have Hung On To And Played On The Way Up.
Well, Two Years From Now This Will Be One Of Those Stocks.
This Is A $20 To $30 Stock In My Opinion. At Least $15 Anyway.
But Nothing Goes Straight Up. And That's Good, Because This
Is One To Nurture On The Way Up. Keep A 50% Core Position
In Case You Screw Up. Play The Technicals On The Rest To
Increase Your Position, While Skimming Profit Off The Top
To Satisfy Your Own Personal Goals.
No Need To Pump Or Bash This Either To Create The Action.
This Is The Real Deal... Ignore The Kids Stuff. There Are Plenty
Of Traders That Will Create It's Own Action. Basically, This Is
On Auto-Pilot And Is Heading Into A Long & Strong Uptrend.
Keep The Board Melo And Real. There Is No Reason To Go
Over The Edge On Pumping Or Bashing. Just Play The Hole.
Walk Softly And Carry A Big Stick... This Is A Good One.
........................................................................
IMPROVED FACTORS
1) Revenues Increased To Almost $26M
* Second Best In Company's History
2) Gross Margins Then Jumped To 33%
* Second Best In Company's History
3) Pre-Split EPS = ($0.03) ---> 10 Cents Better
The Post-Split EPS Number Equals ($0.46)
Which Beat The Analyst Estimates Of ($1.23)
That Estimate Was Beat By 77 Cents, Or 63%
* The Best EPS In The Company's History
EMBEDDED REVENUE STREAMS
This Company Is Weaving A Global Web
Which Is Supplying A Proprietary Game
Changing And Disruptive Technology Of
New Foundational Building Blocks For
1000's Of Compounds & Products On A
World Class Scale, Including Big Pharma.
Major Companies Are Willing To Collaborate
To Reduce Their Costs, While Allowing To
Share Their Future Billions In Profits.
........................................................................
2016 TOTAL ACTUAL REVENUES
Product $26M + Collabs $41M = $67M
2017 TOTAL REVENUE ESTIMATES
Product $60M + Collabs $55M = $115M
2018 PRODUCT REV SET TO DOUBLE
Plus More & Better Collabs And Catalysts
Product $130M + Other $70M = $200M ???
HEADING INTO GROWTH
Product Revenues Are Starting To Ramp Up.
Gross Margins Are Stabilizing And Improving.
EPS And EBITDA Are Heading To Breakeven.
More And Better Collaborations On The Way.
Total Costs & OpEx Will Adjust With Growth.
JMO
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +0,70 | |
| +13,25 | |
| +1,68 | |
| +1,82 | |
| +0,85 | |
| -3,60 | |
| +0,83 | |
| +0,31 | |
| +0,74 | |
| +2,32 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 236 | ||
| 118 | ||
| 100 | ||
| 88 | ||
| 59 | ||
| 39 | ||
| 36 | ||
| 35 | ||
| 32 | ||
| 31 |
| Zeit | Titel |
|---|---|
| 12.09.23 | |
| 26.08.23 |